Pulse Biosciences, Inc (PLSE) Stock Analysis

Pulse Biosciences received FDA IDE approval for the pivotal U.S. trial of the nPulse Cardiac Surgical System in September 2025 and FDA IDE approval for the nPulse Cardiac Catheter System in December 2025, targeting atrial fibrillation — a condition affecting an estimated 43 million people worldwide and representing a greater than $3.0 billion addressable market within electrophysiology. The company received 510(k) clearance for the Vybrance Percutaneous Electrode System in March 2024, with a second electrode size cleared in August 2024. Pulse Biosciences employed 116 people as of December 31, 2025, with no significant revenue from operations.

Pulse Biosciences currently earns minimal revenue from the Vybrance Percutaneous Electrode System, a disposable needle electrode for nonthermal soft tissue ablation placed at sites under short-term evaluation and early commercial agreements, with more than 300 patient procedures completed to date. The two primary development programs are the nPulse Cardiac Surgical Clamp — targeting the Cox-Maze surgical procedure with a single-arm pivotal trial of up to 136 patients at up to 20 sites — and the nPulse Cardiac Catheter, whose European first-in-human study across nine investigators showed 96% procedural success of evaluable patients at one year, as presented by Dr. Vivek Reddy at the AF Symposium in February 2026. Competitors including Abbott Laboratories, AtriCure, Inc., Boston Scientific Corporation, Johnson & Johnson (Biosense Webster), and Medtronic plc all have more established manufacturing, sales, and clinical resources. The company has historically funded operations through equity sales with no assurance that adequate capital will be available on favorable terms.